Breaking Down BML, Inc. Financial Health: Key Insights for Investors

BML, Inc. (4694.T) is showing measurable momentum-TTM revenue of JPY 147.45 billion (up 5.90% year-over-year) and first-half fiscal 2025 net sales rising 6%-while fiscal 2025 annual revenue reached JPY 143.19 billion; profitability metrics reveal a TTM net income of JPY 7.06 billion with a 4.79% net margin, EPS of JPY 181.84 and an operating margin of 6.86%, cash generation is strong (operating cash flow JPY 17.94 billion, free cash flow JPY 10.55 billion) with a net cash position of JPY 65.00 billion, liquidity ratios (current 2.61, quick 2.44) and an Altman Z-Score of 4.05 signaling low bankruptcy risk, while valuation metrics (TTM P/E 13.7, EV/EBITDA 4.51, P/B 1.12) and market cap of JPY 145.44 billion frame the stock for investors weighing competitive, regulatory, and technological risks against clear growth opportunities in automation, diversified testing, and AI-driven diagnostics-read on for a detailed line-by-line breakdown of these figures and what they mean for investors.

BML, Inc. (4694.T) Revenue Analysis

BML, Inc. (4694.T) has shown consistent top-line expansion across recent reporting periods, supported by steady revenue-per-employee productivity and a market cap that underscores its position in the healthcare sector.

• First half of fiscal 2025: net sales rose 6.0% versus the same period a year earlier.
• Trailing twelve months (TTM) revenue as of September 30, 2025: JPY 147.45 billion (YoY +5.90%).
• Fiscal year ending March 31, 2025: annual revenue JPY 143.19 billion (YoY +3.79%).
• Revenue per employee: ~JPY 32.35 million, indicating efficient workforce utilization.
• Five-year compound/average revenue growth: ~3.60% annually, reflecting stable expansion.
• Market capitalization: JPY 145.44 billion, signaling material scale within healthcare.

Key implications for investors include revenue stability with modestly accelerating short-term growth (H1 & TTM), solid revenue productivity per head, and market-cap support for strategic initiatives and M&A optionality. For context on corporate direction, see Mission Statement, Vision, & Core Values (2026) of BML, Inc.

BML, Inc. (4694.T) Profitability Metrics

Key profitability indicators for BML, Inc. (4694.T) show solid top-line earnings conversion and controlled operating costs through the trailing twelve months and the latest reported quarter.

• Q1 FY2025 operating profit increased 10.1% year-over-year.
• TTM net income (as of 30 Sep 2025): JPY 7.06 billion.
• TTM EPS: JPY 181.84.
• Net profit margin (TTM): 4.79%.
• Operating margin (TTM): 6.86%.
• EBITDA margin (TTM): 12.74%.
• Return on equity (ROE): 5.58%.

Interpretation of these metrics points to effective cost control (operating margin 6.86%) and robust EBITDA generation (12.74%), while net margin and ROE indicate moderate bottom-line conversion and shareholder returns. For deeper investor positioning and ownership details, see: Exploring BML, Inc. Investor Profile: Who's Buying and Why?

BML, Inc. (4694.T) - Debt vs. Equity Structure

• Equity-heavy structure: Equity of JPY 130.01 billion vs. liabilities of JPY 42.82 billion implies strong capitalization and low leverage.
• Significant net cash: JPY 65.00 billion net cash supports flexibility for M&A, share buybacks, dividends, or cushioning downturns.
• Very high interest coverage: 84.25x suggests interest obligations are trivial relative to operating earnings, reducing refinancing and default risk.
• Healthy liquidity: Current ratio 2.61 and quick ratio 2.44 indicate robust ability to meet short-term obligations without asset distress.

• Low financial leverage reduces probability of covenant breaches and increases resilience to earnings volatility.
• Strong cash buffer lowers immediate need for external financing, allowing opportunistic investments or shareholder returns.
• Conservative balance sheet may limit return-on-equity compared with more levered peers but improves downside protection.

BML, Inc. (4694.T) - Liquidity and Solvency

• Operating cash flow (TTM): JPY 17.94 billion
• Capital expenditures (TTM): JPY 7.39 billion
• Free cash flow (TTM): JPY 10.55 billion
• Altman Z-Score: 4.05 (low bankruptcy risk)
• Piotroski F-Score: 5 (moderate financial strength)
• Effective tax rate: 33.33%

• Cash coverage: FCF of JPY 10.55B versus capex JPY 7.39B implies remaining cash cushion of JPY 3.16B for other uses.
• Debt-service capacity: strong OCF (JPY 17.94B) and FCF support interest and principal payments; Altman Z-Score 4.05 reduces short-term solvency concerns.
• Operational resilience: Piotroski F-Score of 5 suggests mixed signals-improvements possible in profitability or efficiency to raise the score.
• Tax impact: a 33.33% effective tax rate materially reduces net cash available; tax planning can influence distributable cash.

BML, Inc. (4694.T) Valuation Analysis

• Trailing twelve months (TTM) P/E: 13.7 - implies a reasonable price relative to recent earnings.
• Forward P/E: 20.62 - reflects investor expectations of earnings growth or higher future risk-adjusted valuation.
• Price-to-book (P/B): 1.12 - market values the firm close to its book equity, indicating limited intangible premium.
• Enterprise value (EV): JPY 84.77 billion - captures total firm value including debt and cash considerations.
• EV/EBITDA: 4.51 - signals efficient earnings generation versus enterprise value.
• EV/FCF: 8.03 - suggests the firm's free cash flow supports a reasonable valuation multiple.
• Market capitalization: JPY 145.44 billion - positions BML as a meaningful mid-to-large cap within healthcare.

• Relative strengths: attractive EV/EBITDA and EV/FCF multiples suggest efficient conversion of enterprise value into operating earnings and cash.
• Potential watch points: forward P/E at ~20.6 indicates the market expects earnings improvement - monitor guidance and analyst revisions.
• Valuation context: P/B near 1.12 implies limited goodwill or premium priced in; compare to peers for sector-specific asset intensity.

BML, Inc. (4694.T) - Risk Factors

• BML operates in a competitive diagnostic services market, facing pressure from both domestic and international players. Large clinical laboratory chains, hospital-owned labs and overseas entrants compress pricing power and reimbursement rates.
• The company is exposed to regulatory changes in the healthcare sector, which could impact operations. Revisions to fee schedules, privacy and data laws, or inspection standards can alter revenue and compliance costs.
• Technological advancements may render some of BML's services obsolete, affecting revenue streams. Emergent molecular diagnostics, point‑of‑care testing and AI-driven interpretation can reduce demand for legacy assays.
• Economic downturns can lead to reduced healthcare spending, potentially impacting demand for diagnostic services-especially elective screenings and non-urgent tests.
• The aging population in Japan may increase demand for healthcare services, but also intensify competition as more providers vie for geriatric diagnostic volumes.
• Fluctuations in currency exchange rates can affect profitability, especially if the company has international procurement or revenue exposure denominated in foreign currencies.

• Macro context and measurable drivers:
  • Japan's population aged 65+ is roughly 28-29% (2023 data), supporting long‑term demand for diagnostics but intensifying provider competition.
  • Healthcare spending in Japan is around 10-11% of GDP, implying a large, but cost‑conscious, public payer environment.
  • FX: historical JPY volatility can swing equipment and reagent costs - multi‑year moves of 20-35% versus USD/major currencies are not uncommon and materially affect margins if foreign procurement is significant.
• Operational sensitivities:
  • Concentration risk - reliance on a limited number of high‑volume assays or key hospital networks increases downside if contracts are lost.
  • CapEx and R&D needs - to remain competitive, BML must invest in newer platforms (molecular, NGS, AI), which can temporarily depress free cash flow.
• Mitigants and monitoring signals:
  • Contract renewal cadence and loss/gain of major accounts - monitor client mix and churn rates.
  • R&D and capex spend trends - increases suggest proactive technology adoption; shrinking spend may raise disruption risk.
  • FX hedging policy and reported foreign‑currency exposure - look for hedging ratios in disclosures.

BML, Inc. (4694.T) - Growth Opportunities

• Automation adoption (Frontier, Symphony systems) - improves throughput and reduces per-sample cost.
• Expansion into food safety testing and environmental monitoring - taps growing regulatory-driven demand.
• Service diversification into specialized testing (molecular assays, allergen panels, contaminants) - lowers single-segment concentration risk.
• Strategic partnerships and M&A - accelerates geographic and capability expansion.
• Data analytics and AI integration - enhances diagnostic accuracy and creates value-added services (predictive alerts, client dashboards).

• Deploy Frontier/Symphony automation in high-volume test streams to realize estimated 30%-40% productivity gains and shorten billing cycles.
• Prioritize food safety panels and environmental assays where regulatory testing creates recurring demand, aiming for capture of local market share as those segments expand at ~6%-8% CAGR.
• Target bolt-on acquisitions or partnerships for specialized molecular and contaminant testing to accelerate capability roll-out and cross-sell into existing client relationships.
• Invest in analytics platforms that combine lab results with epidemiological and supply-chain data to create subscription services and higher-margin advisory offerings.
• Use the company's legacy (since 1955) and brand trust to negotiate long-term contracts with industrial and public-sector clients for recurring revenue streams.